menu
    • menu
    [{"orgOrder":0,"company":"HiberCell","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"HC-7366","moa":"||GCN2","graph1":"Oncology","graph2":"Phase I","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"HiberCell \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"HiberCell \/ Merck & Co"},{"orgOrder":0,"company":"HiberCell","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Odetiglucan","moa":"||Dectin-1 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HiberCell \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"HiberCell \/ Merck & Co"},{"orgOrder":0,"company":"HiberCell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"HC-5404","moa":"Endoplasmic reticulum stress","graph1":"Oncology","graph2":"Phase I","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"HiberCell \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"HiberCell \/ Inapplicable"},{"orgOrder":0,"company":"HiberCell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"HC-5404","moa":"PERK","graph1":"Oncology","graph2":"Phase I","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"HiberCell \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"HiberCell \/ Inapplicable"},{"orgOrder":0,"company":"HiberCell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"HC-7366","moa":"||GCN2","graph1":"Oncology","graph2":"Phase I","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HiberCell \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"HiberCell \/ Inapplicable"},{"orgOrder":0,"company":"HiberCell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"HC-7366","moa":"||GCN2","graph1":"Oncology","graph2":"Phase I","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"HiberCell \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"HiberCell \/ Inapplicable"},{"orgOrder":0,"company":"HiberCell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"HC-7366","moa":"GCN2","graph1":"Oncology","graph2":"Phase I","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"HiberCell \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"HiberCell \/ Inapplicable"},{"orgOrder":0,"company":"HiberCell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"HC-7366","moa":"||GCN2","graph1":"Oncology","graph2":"Phase I","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"HiberCell \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"HiberCell \/ Inapplicable"},{"orgOrder":0,"company":"HiberCell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Odetiglucan","moa":"||Dectin-1 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HiberCell \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"HiberCell \/ Inapplicable"},{"orgOrder":0,"company":"HiberCell","sponsor":"Celldex Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"CDX-1140","moa":"||Dectin-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HiberCell \/ Celldex Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"HiberCell \/ Celldex Therapeutics"},{"orgOrder":0,"company":"HiberCell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Odetiglucan","moa":"||Dectin-1 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HiberCell \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"HiberCell \/ Inapplicable"},{"orgOrder":0,"company":"HiberCell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Odetiglucan","moa":"||Dectin-1 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HiberCell \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"HiberCell \/ Inapplicable"},{"orgOrder":0,"company":"HiberCell","sponsor":"Imprime PGG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Odetiglucan","moa":"||Dectin-1 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HiberCell \/ Imprime PGG","highestDevelopmentStatusID":"8","companyTruncated":"HiberCell \/ Imprime PGG"},{"orgOrder":0,"company":"HiberCell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Odetiglucan","moa":"||Dectin-1 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HiberCell \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"HiberCell \/ Inapplicable"},{"orgOrder":0,"company":"HiberCell","sponsor":"Labcorp Drug Development","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"HC-7366","moa":"GCN2","graph1":"Oncology","graph2":"Phase I","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule, Immediate Release","sponsorNew":"HiberCell \/ Labcorp Drug Development","highestDevelopmentStatusID":"6","companyTruncated":"HiberCell \/ Labcorp Drug Development"},{"orgOrder":0,"company":"HiberCell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"HC-7366","moa":"GCN2","graph1":"Oncology","graph2":"Phase I","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"HiberCell \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"HiberCell \/ Inapplicable"},{"orgOrder":0,"company":"HiberCell","sponsor":"Labcorp Drug Development","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"HC-5404","moa":"Endoplasmic reticulum stress","graph1":"Oncology","graph2":"Phase I","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"HiberCell \/ Labcorp Drug Development","highestDevelopmentStatusID":"6","companyTruncated":"HiberCell \/ Labcorp Drug Development"}]

    Find Clinical Drug Pipeline Developments & Deals by HiberCell

    Menu

    HiberCell

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            HiberCell

                            U.S.A arrow
                            Interphex
                            Not Confirmed

                            HiberCell

                            U.S.A arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HC-7366,Azacitidine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            HiberCell Gets FDA Fast Track for HC-7366 in Relapsed AML

                            Details : HC-7366 is a first-in-class, first-in-human, selective, potent, small molecule activator of the general control nonderepressible 2 (GCN2) kinase. It is being evaluated for the treatment of r/r AML.

                            Product Name : HC-7366

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 23, 2024

                            Lead Product(s) : HC-7366,Azacitidine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            HiberCell

                            U.S.A arrow
                            Interphex
                            Not Confirmed

                            HiberCell

                            U.S.A arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HC-7366,Azacitidine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            HiberCell Doses First Patient in Phase 1b Trial of HC-7366 in AML Treatment

                            Details : HC-7366 is a first-in-human, small molecule activator of the GCN2 kinase, which is being evaluated in combination with venetoclax and azacitidine in AML patients.

                            Product Name : HC-7366

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 28, 2024

                            Lead Product(s) : HC-7366,Azacitidine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            HiberCell

                            U.S.A arrow
                            Interphex
                            Not Confirmed

                            HiberCell

                            U.S.A arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HC-7366,Belzutifan

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            HiberCell Doses First Patient in Merck Collaboration for Advanced ccRCC

                            Details : HC-7366, a selective activator of general control nonderepressible 2 kinases, is under investigation with Welireg for clear cell renal cell carcinoma treatment.

                            Product Name : HC-7366

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 05, 2024

                            Lead Product(s) : HC-7366,Belzutifan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            HiberCell

                            U.S.A arrow
                            Interphex
                            Not Confirmed

                            HiberCell

                            U.S.A arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HC-5404

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            HiberCell Announces Successful Completion and Interim Results of Phase 1 Study of Novel PERK Inhibitor, HC-540...

                            Details : HC-5404 is a first-in-class, first-in-human selective and potent PKR-like endoplasmic reticulum kinase (PERK) inhibitor. Itis being evaluated in phase 1 clinical trials for the treatment of solid tumors.

                            Product Name : HC-5404

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 27, 2023

                            Lead Product(s) : HC-5404

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            HiberCell

                            U.S.A arrow
                            Interphex
                            Not Confirmed

                            HiberCell

                            U.S.A arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Odetiglucan,CDX-1140

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Celldex Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            HiberCell Doses First Patient in Phase 1b Study Exploring Novel Combination of Odetiglucan and CD40 Agonistic ...

                            Details : Imprime PGG (odetiglucan) is a pathogen-associated molecular pattern which is designed to enhance innate immune functions, including cytotoxic effector mechanisms, to reverse immunosuppression and facilitate cross-talk with the adaptive immune system.

                            Product Name : Imprime PGG

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 22, 2023

                            Lead Product(s) : Odetiglucan,CDX-1140

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Celldex Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            HiberCell

                            U.S.A arrow
                            Interphex
                            Not Confirmed

                            HiberCell

                            U.S.A arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HC-7366,Belzutifan

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Merck & Co

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            HiberCell, Inc. Announces Clinical Collaboration with Merck to Evaluate HC-7366, an Activator of ISR Kinase GC...

                            Details : The collaboration aims to evaluate HiberCell's HC-7366, a selective activator of the general control nonderepressible 2 kinases in combination with Welireg (belzutifan), Merck’s oral HIF-2α inhibitor for the treatment of clear cell renal cell carcinom...

                            Product Name : HC-7366

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            May 12, 2023

                            Lead Product(s) : HC-7366,Belzutifan

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Merck & Co

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            HiberCell

                            U.S.A arrow
                            Interphex
                            Not Confirmed

                            HiberCell

                            U.S.A arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HC-7366

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            HiberCell Maps Forward Path for Novel GCN2 Activator, HC-7366 in Acute Myeloid Leukemia (AML)

                            Details : HC-7366, a first-in-class, first-in-human GCN2 activator. In preclinical studies, HC-7366 was observed to have robust anti-tumor and immunomodulatory activity in a variety of models of solid tumors and hematological malignancies.

                            Product Name : HC-7366

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 22, 2023

                            Lead Product(s) : HC-7366

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            HiberCell

                            U.S.A arrow
                            Interphex
                            Not Confirmed

                            HiberCell

                            U.S.A arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Odetiglucan,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            HiberCell to Present Posters on Novel Candidates Odetiglucan and HC-7366 at the 2022 Annual American Society o...

                            Details : Imprime PGG (odetiglucan) is a pathogen-associated molecular pattern which is designed to enhance innate immune functions, including cytotoxic effector mechanisms, to reverse immunosuppression and facilitate cross-talk with the adaptive immune system.

                            Product Name : Imprime PGG

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 24, 2022

                            Lead Product(s) : Odetiglucan,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            HiberCell

                            U.S.A arrow
                            Interphex
                            Not Confirmed

                            HiberCell

                            U.S.A arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Odetiglucan,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            HiberCell Announces First Patients Dosed in Phase 2 Clinical Trial of Odetiglucan in Combination with KEYTRUDA...

                            Details : Odetiglucan, a novel intravenously administered investigational innate and adaptive immune modulator, has previously been investigated in combination with pembrolizumab in immune checkpoint inhibitor-naive metastatic triple negative breast cancer patient...

                            Product Name : Imprime PGG

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 28, 2022

                            Lead Product(s) : Odetiglucan,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            HiberCell

                            U.S.A arrow
                            Interphex
                            Not Confirmed

                            HiberCell

                            U.S.A arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Odetiglucan,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Imprime PGG

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            HiberCell to Present Clinical Applications of Odetiglucan and the Role of Beta-Glucan in Cancer Treatment

                            Details : Odetiglucan or Imprime PGG, a Dectin-1, pattern recognition receptor agonist, is currently in phase 2 clinical trial in combination with pembrolizumab, an anti-programmed death receptor-1 therapy used in cancer immunotherapy, for treatment of metastatic ...

                            Product Name : Imprime PGG

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 03, 2022

                            Lead Product(s) : Odetiglucan,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Imprime PGG

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth